Roivant Sciences Ltd.

Roivant Sciences is a clinical-stage biopharmaceutical company headquartered in London that discovers, develops, and commercializes therapeutic candidates and delivery technologies, primarily for immunological and respiratory diseases. The company's pipeline spans multiple therapeutic areas, with mosliciguat, an inhaled soluble guanylate cyclase activator, serving as its lead program for pulmonary hypertension associated with interstitial lung disease. Additional clinical candidates include IMVT-1402, a monoclonal antibody targeting the neonatal Fc receptor for autoimmune conditions such as Graves' disease and rheumatoid arthritis; batoclimab for thyroid eye disease; and brepocitinib, a TYK2 and JAK1 inhibitor in development for immune-mediated diseases including dermatomyositis and non-infectious uveitis.

Beyond individual drug candidates, Roivant has developed proprietary delivery platforms including a lipid nanoparticle technology and ligand conjugate platform intended to enhance therapeutic efficacy. The company operates with approximately 750 full-time employees and maintains a market capitalization of $20.1 billion. As a Nasdaq-listed entity incorporated in Bermuda, Roivant remains focused on clinical development with no disclosed revenue-generating products currently on the market. The company's therapeutic focus centers on areas with high unmet medical need, particularly autoimmune and respiratory conditions where existing treatment options are limited or inadequate.